HUP9701945A1 - Ciklodextrint és taxánszármazékot tartalmazó injekciós gyógyszerkészítmény - Google Patents

Ciklodextrint és taxánszármazékot tartalmazó injekciós gyógyszerkészítmény

Info

Publication number
HUP9701945A1
HUP9701945A1 HU9701945A HUP9701945A HUP9701945A1 HU P9701945 A1 HUP9701945 A1 HU P9701945A1 HU 9701945 A HU9701945 A HU 9701945A HU P9701945 A HUP9701945 A HU P9701945A HU P9701945 A1 HUP9701945 A1 HU P9701945A1
Authority
HU
Hungary
Prior art keywords
preparation
cyclodextrin
taxoids
pharmaceutical composition
injection containing
Prior art date
Application number
HU9701945A
Other languages
English (en)
Inventor
Joseph M. Géczy
Original Assignee
Thissen Laboratoires S.A.
CYCLOLAB Ciklodextrin Kutató- Fejlesztő Kft.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thissen Laboratoires S.A., CYCLOLAB Ciklodextrin Kutató- Fejlesztő Kft. filed Critical Thissen Laboratoires S.A.
Priority to HU9701945A priority Critical patent/HUP9701945A3/hu
Publication of HU9701945D0 publication Critical patent/HU9701945D0/hu
Priority to ZA989779A priority patent/ZA989779B/xx
Priority to ARP980105607A priority patent/AR015482A1/es
Priority to NZ504098A priority patent/NZ504098A/xx
Priority to BR9814015-9A priority patent/BR9814015A/pt
Priority to PL340505A priority patent/PL199652B1/pl
Priority to IL13599098A priority patent/IL135990A0/xx
Priority to AT98955818T priority patent/ATE387916T1/de
Priority to CA2309326A priority patent/CA2309326C/en
Priority to KR1020007005076A priority patent/KR100607391B1/ko
Priority to AU12538/99A priority patent/AU742036B2/en
Priority to EA200000494A priority patent/EA002776B1/ru
Priority to PCT/HU1998/000097 priority patent/WO1999024073A1/en
Priority to JP2000520158A priority patent/JP3656550B2/ja
Priority to EP98955818A priority patent/EP1059942B1/en
Priority to CNB988110105A priority patent/CN1222321C/zh
Priority to DE69839224T priority patent/DE69839224T2/de
Publication of HUP9701945A1 publication Critical patent/HUP9701945A1/hu
Priority to NO20002165A priority patent/NO329382B1/no
Publication of HUP9701945A3 publication Critical patent/HUP9701945A3/hu
Priority to US11/542,797 priority patent/US7671042B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya vízben őldódó gyógyszerkészítmény és ennek vizesőldószerrel képezett őldatai. A készítmény összetétele: A) finőm előszlású, nagy fajlagős felületű (előnyösen: liőfilizált)taxőid, mint paklitaxel vagy dőcetaxel, vagy pőlimőrf hidrátja vagyszőlvátja, és B) nagy fajlagős felületű, amőrf, előnyösen liőfilizált acetil-g-ciklődextrin, vagy hidrőxi-prőpil--ciklődextrin, ahől a taxőid és aciklődextrin tömegaránya az 1:25 és 1:250 közötti tartőmányban van;tővábbá C) kívánt esetben más, a parenterálisan alkalmazőttgyógyszerkészítményeknél szőkásős, vízben őldódó segédanyag. Atalálmány a készítmény előállítására és alkalmazásaira is vőnatkőzik. ŕ
HU9701945A 1997-11-10 1997-11-10 Pharmaceutical composition for injection containing cyclodextrin and taxoids HUP9701945A3 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
HU9701945A HUP9701945A3 (en) 1997-11-10 1997-11-10 Pharmaceutical composition for injection containing cyclodextrin and taxoids
ZA989779A ZA989779B (en) 1997-11-10 1998-10-27 Injectable pharmaceutical compositions containing cyclodextrins
ARP980105607A AR015482A1 (es) 1997-11-10 1998-11-06 Una composicion farmaceutica solida y soluble en agua que contiene un taxoide y una ciclodextrina, sus soluciones en disolventes acuosos para usoparenteral, un procedimiento para su preparacion, un metodo para prevenir la autoagregacion y la precipitacion prematura de un taxoide del grupo delpaclita
DE69839224T DE69839224T2 (de) 1997-11-10 1998-11-09 Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide
CA2309326A CA2309326C (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
PCT/HU1998/000097 WO1999024073A1 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
PL340505A PL199652B1 (pl) 1997-11-10 1998-11-09 Sposób wytwarzania stałych kompozycji farmaceutycznych
IL13599098A IL135990A0 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
AT98955818T ATE387916T1 (de) 1997-11-10 1998-11-09 Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide
NZ504098A NZ504098A (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
KR1020007005076A KR100607391B1 (ko) 1997-11-10 1998-11-09 시클로덱스트린 및 탁소이드를 함유하는 약제학적 조성물
AU12538/99A AU742036B2 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
EA200000494A EA002776B1 (ru) 1997-11-10 1998-11-09 Фармацевтические композиции, содержащие циклодекстрины и таксоиды
BR9814015-9A BR9814015A (pt) 1997-11-10 1998-11-09 Processo para preparação de produtos sólidos instantaneamente solúveis para uso farmacêutico, ditos produtos, método de prevenção e tratamento
JP2000520158A JP3656550B2 (ja) 1997-11-10 1998-11-09 シクロデキストリンとタキソイドを含有する薬剤組成物
EP98955818A EP1059942B1 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids
CNB988110105A CN1222321C (zh) 1997-11-10 1998-11-09 含有环糊精和紫杉醇类物质的药物组合物
NO20002165A NO329382B1 (no) 1997-11-10 2000-04-27 Fremgangsmate for fremstilling av umiddelbart loselige, faste produkter, selve produktet samt anvendelse derav og fremgangsmate for forebyggelse av selvaggregering og prematur utfelling av et taksoid
US11/542,797 US7671042B2 (en) 1997-11-10 2006-10-04 Pharmaceutical compositions containing cyclodextrins and taxoids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9701945A HUP9701945A3 (en) 1997-11-10 1997-11-10 Pharmaceutical composition for injection containing cyclodextrin and taxoids

Publications (3)

Publication Number Publication Date
HU9701945D0 HU9701945D0 (en) 1998-01-28
HUP9701945A1 true HUP9701945A1 (hu) 1999-09-28
HUP9701945A3 HUP9701945A3 (en) 2000-04-28

Family

ID=89995733

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9701945A HUP9701945A3 (en) 1997-11-10 1997-11-10 Pharmaceutical composition for injection containing cyclodextrin and taxoids

Country Status (19)

Country Link
US (1) US7671042B2 (hu)
EP (1) EP1059942B1 (hu)
JP (1) JP3656550B2 (hu)
KR (1) KR100607391B1 (hu)
CN (1) CN1222321C (hu)
AR (1) AR015482A1 (hu)
AT (1) ATE387916T1 (hu)
AU (1) AU742036B2 (hu)
BR (1) BR9814015A (hu)
CA (1) CA2309326C (hu)
DE (1) DE69839224T2 (hu)
EA (1) EA002776B1 (hu)
HU (1) HUP9701945A3 (hu)
IL (1) IL135990A0 (hu)
NO (1) NO329382B1 (hu)
NZ (1) NZ504098A (hu)
PL (1) PL199652B1 (hu)
WO (1) WO1999024073A1 (hu)
ZA (1) ZA989779B (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031286A1 (fr) 2006-09-12 2008-03-20 Nanjing Normal University Composition pharmaceutique contenant une inclusion de cyclodextrine/paclitaxel et procédé de fabrication

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
CA2454913A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
CA2495899A1 (en) * 2002-08-15 2004-03-18 Yunqing Liu Solid nano pharmaceutical formulation and preparation method thereof
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101020059B (zh) * 2006-02-15 2011-01-05 中国科学院上海药物研究所 一种含多烯紫杉醇类物质的药物组合物及其制备方法
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
WO2007142440A1 (en) * 2006-06-02 2007-12-13 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same
KR100917810B1 (ko) * 2006-06-02 2009-09-18 에스케이케미칼주식회사 저장안정성이 우수한 파클리탁셀 함유 주사제 조성물
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
CN102014918A (zh) * 2007-04-20 2011-04-13 太阳医药工业有限公司 由微量沉淀产生的药学组合物
US20080319048A1 (en) * 2007-06-22 2008-12-25 Scidose Llc Solubilized formulation of docetaxel without tween 80
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
KR20120130740A (ko) * 2011-05-23 2012-12-03 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
US11406595B2 (en) * 2012-05-21 2022-08-09 University Of Maryland, College Park Highly stable colloid from aqueous solutions of small organic molecules
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
CA2893881C (en) 2012-12-11 2020-09-22 Sapiotec Gmbh Delphinidin for combating melanoma cells
CN105823810A (zh) * 2016-01-04 2016-08-03 杭州电子科技大学 紫杉醇化疗效果检测装置及检测方法
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
KR102262743B1 (ko) 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
JP7274785B2 (ja) 2018-07-25 2023-05-17 ビカ バイオテクノロジー （グアンジョウ） カンパニー リミテッド 注射用ドセタキセル組成物およびそのための調製法
CA3217204A1 (en) * 2021-05-26 2022-12-01 Daewoong Pharmaceutical Co., Ltd. New formulation for injection comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN115960834B (zh) * 2023-03-07 2023-06-09 浙江省肿瘤医院 一种pd-1/ptx联合pd-1耐药模型建立的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法および用途
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
DE4414138A1 (de) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Acylierte gamma-Cyclodextrine
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
CA2163837C (en) * 1994-12-13 1999-07-20 Robert K. Perrone Crystalline paclitaxel hydrates
IL161372A0 (en) * 2001-11-30 2004-09-27 Bristol Myers Squibb Co Crystalline solvates of paclitaxel

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031286A1 (fr) 2006-09-12 2008-03-20 Nanjing Normal University Composition pharmaceutique contenant une inclusion de cyclodextrine/paclitaxel et procédé de fabrication

Also Published As

Publication number Publication date
EA200000494A1 (ru) 2000-10-30
NO20002165D0 (no) 2000-04-27
EP1059942B1 (en) 2008-03-05
AU1253899A (en) 1999-05-31
CA2309326A1 (en) 1999-05-20
US20070087999A1 (en) 2007-04-19
DE69839224D1 (de) 2008-04-17
PL340505A1 (en) 2001-02-12
NZ504098A (en) 2003-06-30
WO1999024073B1 (en) 1999-07-08
DE69839224T2 (de) 2009-04-16
HUP9701945A3 (en) 2000-04-28
CN1222321C (zh) 2005-10-12
IL135990A0 (en) 2001-05-20
CN1281373A (zh) 2001-01-24
AU742036B2 (en) 2001-12-13
US7671042B2 (en) 2010-03-02
CA2309326C (en) 2010-12-21
AR015482A1 (es) 2001-05-02
JP3656550B2 (ja) 2005-06-08
ATE387916T1 (de) 2008-03-15
NO329382B1 (no) 2010-10-04
ZA989779B (en) 1999-04-28
PL199652B1 (pl) 2008-10-31
EA002776B1 (ru) 2002-08-29
WO1999024073A1 (en) 1999-05-20
NO20002165L (no) 2000-07-07
HU9701945D0 (en) 1998-01-28
BR9814015A (pt) 2000-09-26
KR100607391B1 (ko) 2006-08-02
JP2001522816A (ja) 2001-11-20
KR20010031967A (ko) 2001-04-16
EP1059942A2 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
HUP9701945A1 (hu) Ciklodextrint és taxánszármazékot tartalmazó injekciós gyógyszerkészítmény
KR950016783A (ko) 조절 방출용 약학 조성물
BR9808928A (pt) Complexo molecular e liberação controlada dealfa hidroxiácidos
HUP9800688A2 (hu) Gamma-ciklodextrin és retinol, ill. retinolszármazékok komplexei, eljárás ezek előállítására és ezeket tartalmazó kozmetikai és gyógyszerkészítmények
ES2042598T3 (es) Composiciones de pinturas opalescentes para automoviles que contienen pigmento de dioxido de titanio micronizado.
KR870002842A (ko) 싸이클로덱스트린으로 제조되는 7-이소프로폭시-이소플라본의 함유착물과 그를 활성성분으로 함유하는 약리학적 조성물 및 제제
WO2003066005A3 (en) Ansamycins having improved pharmacological and biological properties
HUP9904359A2 (hu) Eljárás metilidén-malonát nanorészecskék előállítására, és adott esetben egy vagy több biológiai hatással rendelkező molekulát tartalmazó nanorészecskék
EP1004318A3 (en) Cyclodextrin composition
AU2001289438A1 (en) Pharmaceutical semi-solid composition of isotretinoin
EP1072652A3 (de) Beschichtungsmittel
DE602004030370D1 (en) Assoziative wasserlösliche celluloseether
FI20002245A0 (fi) Antimikrobinen polyalfaolefiinikoostumus
BR0208274A (pt) Composições antitumorais contendo derivados de taxano
HK1064297A1 (en) Paramagnetic nanoparticle
DE60020878D1 (de) Additionspolymer und polyurethan enthaltende wässrige beschichtungszusammensetzung
NO954545D0 (no) Inklusjonskomplekser av taxol eller taxoter, eller taxus-ekstrakt dannet med syklodekstrin, samt fremstilling og anvendelse derav
HUP9802121A2 (hu) Imidazolinszármazékok, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények
BR9907439A (pt) Resinas de siloxano solúveis de peso molecular ultra-alto
DE60001744D1 (de) Stabilisator für arzneimittel
CA2236641A1 (en) Preparation of fagopyritols and uses therefor
DE60045578D1 (de) Produkt aus seesternen
ATE406152T1 (de) Medizinische aerosolzusammensetzungen mit einer eine amid- und/oder estergruppe enthaltenden exzipientenverbindung
TR200703565T1 (tr) Peroral uygulanabilir antimikrobiyal kompozisyon.
ATE391551T1 (de) Neue dispergierbare kolloidale calixarene-systeme in form von nanoteilchen

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished